The rapid growth in market demand for GLP-1 receptor agonists has exposed structural vulnerabilities in global sterile injectable manufacturing. Contract development and manufacturing organizations are shifting capacity away from standard biologics to support specialized pen-injector assembly lines.
Capital Allocation and M&A Dynamics
Drug makers are increasingly acquiring manufacturing facilities directly rather than relying on third-party CDMOs. This vertical integration strategy aims to secure long-term capacity, stabilize global distribution, and maintain pricing power against compounding market alternatives.